Previous 10 | Next 10 |
Image source: The Motley Fool. Oxford Immunotec Global PLC (NASDAQ: OXFD) Q3 2020 Earnings Call Nov 3, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Oxford Immunotec Global PLC (OXFD) Q3 2020 Earnings Call Transcr...
Oxford Immunotec Global PLC (OXFD) Q3 2020 Results Earnings Conference Call November 3, 2020, 08:00 AM ET Company Participants Matthew McLaughlin - Chief Financial Officer Peter Wrighton-Smith - Chief Executive Officer Conference Call Participants Steven Mah - Piper Sandler Sung Ji Nam - BTIG...
Oxford Immunotec Global PLC (OXFD) Q3 2020 Results Earnings Conference Call November 3, 2020 07:40 AM ET Company Participants Peter Wrighton-Smith - Chief Executive Officer Matt McLaughlin - Chief Financial Officer Conference Call Participants Steven Mah - Piper Sandler Sung Ji Nam - BTIG Chr...
Oxford Immunotec Global (OXFD): Q3 GAAP EPS of -$0.01 beats by $0.04.Revenue of $19.44M (-8.4% Y/Y) beats by $0.73M.Press Release For further details see: Oxford Immunotec Global EPS beats by $0.04, beats on revenue
Third quarter revenue of $ 19.4 million, above guidance of range of $18 - $ 19 million Asia-Pacific region returns to g r owth and sets a new quarterly sales record for the region Europe & rest of world and U.S....
According to a statement, UK Vaccines Taskforce, the U.K. govt body tasked with assessing the suitability of vaccines, Oxford Immunotec (OXFD) will be the only supplier of T cell testing for SARS-CoV-2 responses in new COVID vaccine trials.U.K. Business Secretary Alok Sharma adds U.K. govt wi...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has been selected to provide T cell testing to the UK Vaccines Taskfo...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2020 financial results before the open of the market ...
The FDA has cleared the use of Oxford Immunotec Global PLC's ([[OXFD]] +0.8%) T-SPOT.TB test in people as young as two years old. It was previously approved for use in people at least five years old.The test is available nationally through Quest Diagnostics ([[DGX]] -0.2%) and through regiona...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced that it has received clearance from the FDA to amend the pediatric age limita...
News, Short Squeeze, Breakout and More Instantly...
Oxford Immunotec Global PLC Company Name:
OXFD Stock Symbol:
NASDAQ Market:
Oxford Immunotec Global PLC Website:
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection Canada NewsWire OXFORD , United Kingdom and MARLBOROUGH, Ma...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market t...
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announces an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. Th...